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Abstract
Background: Neuroendocrine activation and local mediators such as transforming growth factor-b1 (TGF-b1) contribute to
the pathobiology of cardiac hypertrophy and failure, but the underlying mechanisms are incompletely understood. We
aimed to characterize the functional network involving TGF-b1, the renin-angiotensin system, and the b-adrenergic system
in the heart.
Methods: Transgenic mice overexpressing TGF-b1 (TGF-b1-Tg) were treated with a b-blocker, an AT1-receptor antagonist, or
a TGF-b-antagonist (sTGFbR-Fc), were morphologically characterized. Contractile function was assessed by dobutamine
stress echocardiography in vivo and isolated myocytes in vitro. Functional alterations were related to regulators of cardiac
energy metabolism.
Results: Compared to wild-type controls, TGF-b1-Tg mice displayed an increased heart-to-body-weight ratio involving both
fibrosis and myocyte hypertrophy. TGF-b1 overexpression increased the hypertrophic responsiveness to b-adrenergic
stimulation. In contrast, the inotropic response to b-adrenergic stimulation was diminished in TGF-b1-Tg mice, albeit
unchanged basal contractility. Treatment with sTGF-bR-Fc completely prevented the cardiac phenotype in transgenic mice.
Chronic b-blocker treatment also prevented hypertrophy and ANF induction by isoprenaline, and restored the inotropic
response to b-adrenergic stimulation without affecting TGF-b1 levels, whereas AT1-receptor blockade had no effect. The
impaired contractile reserve in TGF-b1-Tg mice was accompanied by an upregulation of mitochondrial uncoupling proteins
(UCPs) which was reversed by b-adrenoceptor blockade. UCP-inhibition restored the contractile response to b-adrenoceptor
stimulation in vitro and in vivo. Finally, cardiac TGF-b1 and UCP expression were elevated in heart failure in humans, and UCP
– but not TGF-b1 – was downregulated by b-blocker treatment.
Conclusions: Our data support the concept that TGF-b1 acts downstream of angiotensin II in cardiomyocytes, and
furthermore, highlight the critical role of the b-adrenergic system in TGF-b1-induced cardiac phenotype. Our data indicate
for the first time, that TGF-b1 directly influences mitochondrial energy metabolism by regulating UCP3 expression. b-
blockers may act beneficially by normalizing regulatory mechanisms of cellular hypertrophy and energy metabolism.
Citation: Huntgeburth M, Tiemann K, Shahverdyan R, Schlu ¨ter K-D, Schreckenberg R, et al. (2011) Transforming Growth Factor b1 Oppositely Regulates the
Hypertrophic and Contractile Response to b-Adrenergic Stimulation in the Heart. PLoS ONE 6(11): e26628. doi:10.1371/journal.pone.0026628
Editor: Shahab A. Akhter, University of Chicago, United States of America
Received April 16, 2011; Accepted September 29, 2011; Published November 17, 2011
Copyright:  2011 Huntgeburth et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by the Deutsche Forschungsgemeinschaft (RO1306/2-2 to SR and WHZ, HU1583/2-1 to MH, and SFB656 C3 to KT), the
Center for Molecular Medicine Cologne (CMMC; project A6, to SR), the Ko ¨ln Fortune Program of the Medical Faculty of the University of Cologne (to MH), and by a
research grant from Boehringer-Ingelheim. MB is funded by the Deutsche Forschungsgemeinschaft (KFO 196). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: stephan.rosenkranz@uk-koeln.de
. These authors contributed equally to this work.
Introduction
Transforming growth factor-b1 (TGF-b1) is a 25-kDa homodi-
meric protein that is involved in numerous cellular processes [1,2].
In the heart, TGF-b1 is expressed at high levels during embryonic
development and pathology [3–6]. Both, TGF-b1 ligand and its
two serine-threonine kinase receptors, termed TGF-b receptor
type I and II (TbRI and TbRII), are present in cardiac tissue, and
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26628all are expressed in cardiac myocytes and non-myocytes [4–6].
TGF-b1 has been implicated in a number of cardiac diseases such
as pressure overload hypertrophy, post myocardial infarction
ventricular remodeling, idiopathic hypertrophic cardiomyopathy,
and dilative cardiomyopathy [5,6]. In particular, TGF-b1 is highly
expressed in hypertrophic myocardium during the transition from
stable hypertrophy to heart failure [7], indicating that it may play
a role in the functional deterioration of the hypertrophied heart.
Ventricular remodeling is a dynamic process of alterations in
size, shape and function of the left ventricle that involves adaptive
and/or pathologic changes of cardiac myocytes and interstitial
tissue. It is well established that activation of neuroendocrine
mechanisms such as the renin-angiotensin-aldosterone system
(RAAS) and the sympathetic nervous system as well as the
induction of local mediators contribute to the structural and
functional alterations in the hypertrophied heart [5–12]. TGF-b1
may be a crucial mediator of cardiac remodeling through direct
and indirect actions in cardiomyocyte hypertrophy, fibroblast
proliferation, and extracellular matrix metabolism [5,6]. While
increased TGF-b1 levels were associated with cardiac hypertrophy
and fibrosis [13,14], the loss of one TGF-b1 allele in heterozygous
TGF-b1 deficient mice resulted in decreased fibrosis of the aging
heart [15]. An extensive body of evidence suggests a direct
functional association between TGF-b1, the RAAS and the b-
adrenergic system. Several studies have demonstrated that
angiotensin II induces TGF-b1 mRNA and protein expression in
cardiac myocytes and fibroblasts via the angiotensin type 1 (AT1)
receptor in vitro [4–6], and appears to be required for angiotensin-
induced cardiac hypertrophy in vivo [16]. In addition, TGF-b1 was
shown to modulate the number and function of b-adrenergic
receptors in various cell types [5,17], and to alter b-adrenergic
signaling in the heart in vivo [13,18]. However, the precise
interplay and the functional consequences of the network involving
TGF-b1, the RAAS, and the b-adrenergic system have not been
thoroughly characterized.
To better understand the mechanisms by which TGF-b1
induces cardiac fibrosis and hypertrophy, and furthermore may
contribute to myocardial dysfunction, we took advantage of a
transgenic mouse model that overexpresses a mature form of
TGF-b1. Based on the well established connection between TGF-
b1, the RAAS and the b-adrenergic system, TGF-b1 transgenic
mice were chronically treated with a b-adrenoceptor blocker, an
angiotensin AT1 receptor antagonist, or an antibody against the
TGF-b receptor. The results identify TGF-b1 as an important
regulator of cardiomyocyte growth and function. Furthermore,
our data suggest that the b-adrenergic system is critically involved
in TGF-b1-induced cardiac phenotype, as TGF-b1 promotes the
hypertrophic responsiveness to b-adrenergic stimulation, whereas
it impairs the contractile response to b-adrenergic stimuli by
affecting the energy metabolism in the heart.
Materials and Methods
Animals and treatment
Alb/TGF-b1(cys
223,225ser) transgenic mice were generated and
maintained as described [13,19]. The TGF-b1 cDNA encodes
cysteine-to-serine substitutions at amino acid residues 223 and
225, resulting in preferential secretion of mature TGF-b1 [20].
Mice were treated from week three (immediately after weaning) to
week 8 with either metoprolol (350 mg/kgBW/d) or telmisartan
(10 mg/kgBW/d), each supplied with the drinking water, or by
intraperitoneal application of soluble TGF-b receptor-Fc (sR-Fc;
1 mg/kgBW every other day). The latter compound was
previously shown to act as a potent TGF-b antagonist [21]. All
investigations were carried out at the age of 8 weeks, and all
animal studies were performed according to NIH and Institutional
animal care and use guidelines, and were approved by the local
animal care authorities.
Human heart tissue
Left ventricular tissue was obtained from explanted hearts of
patients with dilative cardiomyopathy (DCM) undergoing heart
transplantation. Groups consisted of patients without beta-blocker
treatment (DCM) and with beta-blocker (metoprolol) treatment. In
DCM hearts, left ventricular ejection fraction (LVEF) was ,40%.
Non-failing controls represent healthy donor hearts that could not
be implanted for whatever reason. The use of myocardial tissue
samples was approved by the local ethics committee, and written
informed consent was obtained from all patients.
Tissue homogenization, isolation of mitochondria and
Western blot analyses
Left ventricular tissue was homogenized by incubation in
extraction buffer (10 mM cacodylic acid, 150 mM NaCl, 1 mM
ZnCl2, 20 mM CaCl2, 1.5 mM NaN3, 0.01% Triton-X100,
pH 5.0) for 12 h at 4uC and subsequent centrifugation for
10 min at 1,2006 g. For isolation of mitochondria, fresh tissue
was repeatedly minced in ice-cold STE, chopped in ice-cold STE
buffer (250 mM sucrose, 5 mM Tris, 2 mM EGTA, pH 7.4 at
4uC) and rinsed. The chopped tissue was subjected to proteinase
digest and disrupted in a Dounce homogenizer with a tight
plunger. The homogenate was centrifuged at 7006 g for
10 minutes at 4uC, the supernatant was filtered through cheese
cloth and centrifuged at 8,0006g for 10 minutes. The pellet was
resuspended in 40 ml of RIPA-buffer, subjected to sonication and
the mitochondrial protein content was assayed using the
bicinchonic acid method (BioRad). Similar amounts of protein
were resolved on a 10% SDS-polyacrylamide electrophoresis gel,
and the proteins were transferred to Immobilon and subjected to
Western blot analysis using antibodies that recognize TGF-b1
(R&D), RasGAP, UCP-3 (Affinity BioReagents), or cytochrome c
oxidase complex IV (COX-I; Invitrogen).
Morphometric analysis of myocardial tissue
Fixation of myocardial tissue was performed by retrograde
perfusion fixation as previously described [22]. Animals were
perfused with either ice-cold NaCl 0.9% (immunohistochemistry)
or 3% glutaraldehyde (morphometric and stereological analysis).
Routine tissue stains were obtained from transversally cut hearts
that were either fixed in 4% buffered formalin or snap-frozen in
Table 1. Oligonucleotide sequences for primer and probe
sets for rat cardiomyocytes.
UCP2 forward
primer
59-TCATCAAAGATACTCTCCTGAAAGC-39
UCP2 reverse
primer
59-TGACGGTGGTGCAGCAGA-39
UCP2 probe 59-FAM-TGACAGACGACCTCCCTTGCCACT-TAMRA-39
UCP3 forward
primer
59-GTGACCTATGACATCATCAAGGA-39
UCP3 reverse
primer
59-GCTCCAAAGGCAGAGACAAAG-39
UCP3 probe 59-FAM-CTGGACTCTTCACCTGTTCACTGACAACTTCC-TAMRA-39
doi:10.1371/journal.pone.0026628.t001
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stained with hematoxylin and eosin. Tissue sampling and section
staining were performed according to the orientator method [23].
Fractional areas of cardiac myocytes, cardiac fibroblasts, and
interstitium were measured on 12 differentially orientated semithin
sections per animal using the point-counting method [22].
Myocyte diameters were measured on longitudinal sections with
a semiautomatic image analyzing system and corrected for
sarcomere length.
RNA isolation and quantitative real-time PCR
For UCP mRNA expression analyses, total RNA was isolated
using the RNeasy Fibrous Tissue Mini Kit (Qiagen). cDNA was
synthesized using the SuperScript III first-strand synthesis system
with random hexamers (Invitrogen). For expression analyses of
atrial natriuretic factor (ANF) and ornithine decarboxylase (ODC),
mouse hearts were isolated and perfused in the Langendorff-mode.
A subset was stimulated with isoprenaline (1 mM), and perfusion
was prolonged for 2 hours. Release of lactate dehydrogenase was
monitored to control for sarcolemmal integrity. Subsequently,
ventricular tissue was dissected and RNA was extracted using
RNA-Clean (AGS, Heidelberg, Germany). Total RNA from
cultured cardiomyocytes was isolated using the TRIzol method
(Invitrogen). Reverse transcription was performed using Sensi-
script reverse transcriptase (Qiagen) and oligo-dt primers for ANF,
ODC, and b-actin as described [13,18]. Quantitative real-time
PCR was performed using TaqMan gene expression assays
(Applied Biosystems) or SYBR Green Master Mix as indicated.
Primers used are listed in table 1. Relative abundance of the gene
of interest was calculated after normalization to 18S ribosomal
RNA or b-actin as indicated.
Dobutamine stress echocardiography
Images were obtained by using a HDI-5000 ultrasound device
(Philips Medical Systems, Bothell, WA, USA) equipped with a
linear array transducer (15 MHz) as described [24]. At least 20
cardiac cycles were obtained for each view, and each imaging
plane was acquired three times to assess reproducibility.
Parasternal short-axis views were divided into six segments, and
long axis views were divided into seven segments [25]. The
endocardial borders were manually traced on the innermost
endocardial edge while the epicardial borders were defined by
tracing along the first bright pixel adjacent to myocardial tissue
[26]. Left ventricular mass (LVM) and LVEF were assessed as
previously described [24]. The resistive index (RI) was calculated
as 1 – enddiastolic velocity/systolic velocity. Dobutamine was
administered intravenously at 10, 20, and 40 mg/kgBW/min after
microscopical cannulation of the tail vein. This procedure
corresponds to the recommended protocol of the American Society
of Echocardiography that is used in humans [27]. 2D- and M-mode
registrations were recorded at each level of dobutamine.
Contractility of isolated cardiac myocytes
Cardiac myocytes were isolated by standard procedures as
described [28]. Briefly, mouse hearts were exposed to collagenase
digest in the Langendorff-mode, minced, and further digested by
incubation with collagenase buffer. The suspension was filtered,
and cardiomyocytes were separated from non-myocytes by
centrifugation. Finally, physiological calcium concentrations were
readjusted by step-wise increases to 1000 nmol/l, and plated on
laminin-coated culture dishes. Cell contraction was investigated
using a cell-edge detection system as previously described [29].
Briefly, cells were stimulated with biphasic electrical stimuli
composed of two equal but opposite rectangular 50-V stimuli of
0.5 ms duration. Each cell was stimulated at 1, 0.5, and 2 Hz for
1 min. Every 15 s the next five contractions were averaged. The
mean of these four measurements at a given frequency was used to
Figure 1. Characterization of myocardial tissue in wild type (WT) and TGF-b1 transgenic mice (TGF-b1) that have been treated with
either metoprolol (METO), telmisartan (TELMI), or soluble TGF-bR-Fc (sR-Fc). (A) Myocardial TGF-b1 protein expression as determined by
Western blotting in heart homogenates from the various groups as indicated. RasGAP served as lysate control. (B) Body weight, heart weight, and
heart/body weight ratio (n=30–57 animals in each group). (C–F) Morphometric analysis of myocardial tissue (n=5–9 animals in each group). Shown
are the fractional areas of connective tissue (C), cardiac fibroblasts (D), cardiac myocytes (E), and cardiomyocyte diameter (F). *p,0.05 vs. WT,
#p,0.05 vs. untreated TGF-b1 mice.
doi:10.1371/journal.pone.0026628.g001
Figure 2. Induction of (A) atrial natriuretic factor (ANF) and (B)
ornithine decarboxylase (ODC) mRNA by isoprenaline in hearts
from TGF-b1 transgenic mice (TGF-b1) that have been treated
with either metoprolol (METO), telmisartan (TELMI), or soluble
TGF-bR-Fc (sR-Fc). Data are expressed as fold-increase relative to
saline-perfused hearts. *p,0.05 vs. WT mice.
doi:10.1371/journal.pone.0026628.g002
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at a rate of 500 Hz via a line camera.
Statistical analyses
All data are expressed as means 6 SEM. Statistical significance
was estimated by ANOVA, followed by post-hoc analysis (Student-
Neuman-Keuls test), or by using the Student’s t-test for paired or
unpaired observations, as appropriate. A p value of less than 0.05
was considered statistically significant.
Results
Cardiac hypertrophy in TGF-b1 transgenic mice is
prevented by chronic b- adrenoceptor blockade
Compared to wild-type mice, transgenic mice overexpressing a
mature form (cys
223,225ser) of TGF-b1 (Fig. 1A) displayed cardiac
hypertrophy, as indicated by an increase in heart weight
(170.563.4 vs. 122.363.4 mg; p,0.05) with no change in body
weight, resulting in a significant increase of the heart-to-body-
weight ratio (6.860.1 vs. 5.160.1 mg/g; p,0.05; Fig. 1B). The
data on cardiac hypertrophy in TGF-b1 transgenic mice have
been published previously [13] and are included here for
completeness. Cardiac hypertrophy was not due to hypertension
as the invasively measured mean arterial blood pressure was
similar in wild type and transgenic mice (99.764.2 vs.
98.964.3 mmHg, n=7 in each group, n.s.). In order to investigate
whether the TGF-b1-induced cardiac phenotype involved neuro-
endocrine activation, TGF-b1 transgenic mice were chronically
treated with the b-adrenoceptor blocker metoprolol, the angio-
tensin AT1 receptor antagonist telmisartan, or a TGF-b antagonist
(sR-Fc). While neither treatment affected the elevated TGF-b1
protein levels in transgenic mice (Fig. 1A), chronic application of
either metoprolol or sR-Fc prevented the increase of the heart-to-
body-weight ratio (5.360.3 and 5.160.2 mg/g, respectively; both
p,0.05 vs. TGF-b1) whereas telmisartan did not prevent cardiac
hypertrophy in transgenic mice (Fig. 1B).
Morphometric analysis of the hearts revealed that the increase
in cardiac size of TGF-b1 transgenic mice was due to both fibrosis
and myocyte hypertrophy (Fig. 1C–F). This is demonstrated by a
significant increase in the fractional areas of connective tissue and
cardiac fibroblasts (Fig. 1C and D), with no change in myocyte
fractional area (Fig. 1E), and a significant increase of cardiomy-
ocyte diameter (Fig. 1F). These morphological changes in TGF-b1
transgenic mice were prevented by b-adrenoceptor blockade with
metoprolol and application of sR-Fc, but not by AT1 receptor
blockade with telmisartan.
TGF-b1 enhances the hypertrophic responsiveness to
bAR agonists
In adult heart muscle cells, cardiomyocyte hypertrophy upon
adrenergic stimulation in vitro is exclusively mediated via the a-
adrenergic receptor [30]. However, our previous studies have
shown that cardiac hypertrophy in TGF-b1 transgenic mice is
accompanied by an increased cardiac expression of hypertrophy-
associated genes such as ANF which is further inducible by b-
adrenergic stimulation in hearts from TGF-b1 but not from wild-
type mice [17,18]. This induction specifically depended on
upregulation of ornithine decarboxylase (ODC), the rate limiting
enzyme of the polyamine metabolism [18]. In line with the
antihypertrophic effect of metoprolol as shown above, chronic b-
adrenoceptor blockade as well as TGF-b antagonism prevented
the induction of both ANF and ODC in isoprenaline-perfused
hearts from TGF-b1 transgenic mice (Fig. 2A and B). In contrast,
blockade of the angiotensin AT1 receptor did not prevent the
induction of ANF and ODC in this model.
TGF-b1 abrogates the contractile response to
b-adrenergic stimulation
Echocardiography confirmed cardiac hypertrophy in TGF-b1
mice in vivo, as LVM was increased in TGF-b1 mice compared to
wild type animals (131.3611.3 vs. 103.4365.92 mg; p,0.05).
Similar to gravimetrical analyses of the hearts, chronic treatment
with metoprolol and sR-Fc prevented cardiac hypertrophy (LVM
109.5611.0 and 82.866.3 mg, respectively; both p,0.05 vs.
TGF-b1), whereas telmisartan did not (Fig. 3A and B). Under basal
conditions, there was no difference in LVEF between wild-type
and TGF-b1 mice (56.263.6 vs. 61.866.7%; n.s.), and none of the
treatments had a significant effect on systolic function (Fig. 3C).
Likewise, the resistive index (RI) as a measure of LV afterload was
similar in all groups (Fig. 3D).
In order to investigate the influence of TGF-b1 overexpression
and the various pharmacological interventions on the contractile
response to b-adrenergic stimuli, we performed dobutamine stress
echocardiography (DSE) in vivo (Fig. 4A and B), and furthermore
measured cell shortening of isolated cardiomyocytes in vitro. DSE
revealed that the inotropic responsiveness to b-adrenergic
stimulation was significantly diminished in TGF-b1 mice. At peak
stress (dobutamine 40 mg/kg/min), the relative increase of LVEF
was 1665% in TGF-b1 mice vs. 4465% in wild-type control mice
(p,0.01). Both metoprolol and sR-Fc completely restored the
inotropic responsiveness to dobutamine (relative increase in LVEF
52610 and 4365%, respectively; both p,0.05 vs. TGF-b1),
whereas telmisartan had no significant effect (Fig. 4C).
To further extend these findings to isolated cells, cardiac
myocytes were isolated from wild-type and TGF-b1 transgenic
mice that had been treated with the various compounds. There
was no difference in basal contractility between cells from wild-
type and TGF-b1 mice. Consistent with the data obtained by DSE,
the contractile response of isolated cardiac myocytes to b-
adrenergic stimulation was diminished in TGF-b1 transgenic mice
(Fig. 5A and B), and was restored by chronic treatment with either
metoprolol or sR-Fc, but not by telmisartan (Fig. 5C).
Mitochondrial uncoupling proteins are involved in the
reduction of contractile reserve in TGF-b1 transgenic
mice
Since our previous studies have demonstrated that hearts from
TGF-b1 mice displayed an increased hypertrophic responsiveness
to b-adrenergic stimulation and an increased contractility of atrial
tissue when compared to wild-type mice [13], the fact that the
contractile response in left ventricular tissue was diminished
appeared surprising and warranted further investigation. To this
end, we focused on mitochondrial uncoupling proteins (UCPs),
which are involved in the regulation of energy metabolism in
Figure 3. Echocardiographic evaluation of wild type (WT) and TGF-b1 transgenic mice (TGF-b1) that have been treated with either
metoprolol (METO), telmisartan (TELMI), or soluble TGF-bR-Fc (sR-Fc). (A) Representative short axis views during diastole and systole in WT
and TGF-b1 mice. (B) Left ventricular mass. (C) Left ventricular ejection fraction at rest. (D) Resistive Index. Data in B–D represent means 6 SEM from
5–7 animals in each group. *p,0.05 vs. WT;
#p,0.05 vs. untreated TGF-b1 mice.
doi:10.1371/journal.pone.0026628.g003
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mitochondrial membrane, thereby causing a ‘‘proton leak’’ that
results in reduced generation of ATP [31]. Our in vitro studies
demonstrated that stimulation of rat cardiac myocytes with TGF-
b1 led to a dramatic upregulation of UCP2 and UCP3 mRNA
(Fig. 6A). Consistently, we found that the protein levels of UCP3
were significantly elevated in cardiac mitochondria that were
isolated from TGF-b1 transgenic mice as compared to wild-type
animals (Fig. 6B). In contrast, the protein levels of mitochondrial
adenosine nucleotide transporter (ANT) and sarco-/endoplasmatic
reticulum calcium-ATPase (SERCA) were not altered in the hearts
of TGF-b1 transgenic mice (not shown). When the cardiac UCP
levels in the various treatment groups were compared, chronic b-
adrenoceptor blockade with metoprolol and TGF-b antagonism
by sR-Fc, but not AT1 receptor blockade with telmisartan,
significantly reduced the elevated mRNA levels of UCP2 and
UCP3 in TGF-b1 mice (Fig. 6C and D), and this correlated with
the ability of whole hearts and cardiac myocytes to adequately
respond to b-adrenergic stimuli (see Figures 4 and 5). Downreg-
ulation of myocardial UCPs by b-adrenoceptor blockade occurred
on the cellular level, as the induction of UCP2 and UCP3 by
TGF-b1 in isolated cardiomyocytes was abolished by pre-
treatment of the cells with metoprolol (not shown).
In order to assess whether UCPs are indeed involved with the
reduced inotropic reserve in TGF-b1 mice, we finally applied a
pharmacological compound, genipin, which was previously shown
to act as a potent UCP inhibitor [32]. When TGF-b1 transgenic
mice were injected with genipin (100 mg/kgBW i.p.), the
contractile response to dobutamine during DSE was restored
and comparable to the response of wild-type mice (relative
increase of LVEF 4264 vs. 4465%; Fig. 6E). Furthermore, while
the contractile response of isolated cardiac myocytes to isoproter-
enol was diminished in cells from untreated TGF-b1 mice, pre-
treatment with genipin (5 mM) reversed this effect, so that cells
from TGF-b1 mice responded better to isoproterenol than cells
from wild-type mice (Fig. 6F). These data indicate that the
expression and activity of UCPs are critically involved in the
determination of the contractile response to b-adrenoceptor
stimulation, and suggest that chronic b-blocker treatment
improves the inotropic reserve in TGF-b1 mice by down-
regulating the increased UCP levels.
TGF-b1 and UCP3 expression in human heart failure
To investigate whether this mechanism may also be relevant in
humans, we measured TGF-b1 and UCP3 expression in non-
failing hearts and in myocardium from patients with DCM who
had either been treated or not been treated with metoprolol. In a
limited number of human samples that was available to us, we
show that TGF-b1 expression was increased in DCM hearts
regardless of b-blocker treatment (Fig. 7A). Interestingly, there was
a clear trend towards an increased expression of UCP3 in DCM
hearts of patients who had not received metoprolol as compared to
non-failing myocardium. In contrast to the expression levels of
TGF-b1, there was lower UCP3 expression in DCM hearts from
metoprolol-treated patients as compared to those who had not
received metoprolol (Fig. 7B). Hence, increased expression of
myocardial UCPs and its downregulation by b-adrenoceptor
blockade is found at least in some patients with heart failure.
Discussion
In this manuscript, we demonstrate that cardiac hypertrophy in
mice overexpressing a mature form of TGF-b1 is accompanied by
the induction of hypertrophic responsiveness to b-adrenergic
stimulation, whereas the contractile b-adrenergic response in LV
was diminished. Further analyses revealed that TGF-b1 impairs
the inotropic reserve via regulation of mitochondrial UCPs which
determine the efficiency of energy metabolism in cardiac
myocytes. In fact, this is the first study to implement a role for
TGF-b1 in influencing mitochondrial energy metabolism in the
heart. As expected, the inhibition of TGF-b signaling by the use of
sR-Fc prevented the cardiac phenotype of TGF-b1 transgenic
mice. Interestingly, chronic b-adrenoceptor blockade was also able
to reverse the morphological and functional changes of the heart,
whereas blockade of the angiotensin AT1 receptor had no
significant effect on the cardiac phenotype.
The applied model of transgenic mice overexpressing mature
TGF-b1 represents a situation of cardiac hypertrophy with
preserved LV function at rest, but diminished contractile reserve.
This scenario, which is manifested clinically as dyspnea on
exertion in humans, is most likely to reflect the situation during the
transition from compensated hypertrophy to overt heart failure. In
this model, cardiac hypertrophy was not due to hypertension since
there was no difference in systemic blood pressure between wild-
type and TGF-b1 transgenic mice. Instead, subcellular mecha-
nisms were identified that provide a molecular explanation for the
TGF-b1-induced cardiac alterations. These include the induction
of ODC, which is required for the hypertrophic responsiveness of
the heart to b-adrenergic stimulation [18], and the upregulation of
myocardial UCPs, which impair the efficiency of the energy
metabolism in muscle cells and thus are thought to contribute to
the development of contractile dysfunction in heart failure [31,33].
UCPs are inner mitochondrial membrane proton transporters that
decrease the proton electrochemical gradient across the inner
mitochondrial membrane, thereby reducing the energy force for
ATP production during respiration [31].
The fact that AT1 receptor blockade was unable to prevent
myocardial hypertrophy and dysfunction may appear surprising.
However, the failure of telmisartan to impede the TGF-b1-induced
cardiac phenotype may actually be expected from previous studies.
Schultz et al. provided direct proof that the hypertrophic
cardiomyocyte growth induced by angiotensin II is mediated by
TGF-b1 in vivo [16]. In line with this study, it was shown by several
experimental approaches that TGF-b1 is required for angiotensin
II-induced cardiomyocyte hypertrophy as it acts downstream of
the AT1 receptor (reviewed in [5]). Hence, in a model of TGF-b1
overexpression, blockade of the AT1 receptor is not expected to
prevent cardiac hypertrophy because its downstream effector is
already upregulated. Therefore, our results are consistent with
previous reports and further support the concept that TGF-b1 acts
as a downstream mediator of angiotensin II in cardiomyocyte
hypertrophy and dysfunction.
While the morphological cardiac alterations that are induced by
TGF-b1 have been described in numerous studies [4–6], only little
information is available on the functional consequences of
increased TGF-b1 activity in the heart. We have previously shown
that overexpression of TGF-b1 in transgenic mice was associated
Figure 4. Dobutamine stress echocardiography (DSE). (A) DSE protocol as applied in mice. (B) Representative m-mode registrations in a WT
mouse at rest, and at various concentrations of dobutamine (Dobu). (C) Contractile reserve in response to cumulative concentrations of dobutamine
in wild type (WT) and TGF-b1 transgenic mice (TGF-b1) that have been treated with either metoprolol (METO), telmisartan (TELMI), or soluble TGF-bR-
Fc (sR-Fc), n=5–6 in each group. *p,0.05 vs. rest;
#p,0.05 vs. WT.
doi:10.1371/journal.pone.0026628.g004
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downregulation of negative regulators such as Gia and bARK-1,
resulting in increased contractility of the atria in TGF-b1
transgenic mice [13]. While the induction of a hypertrophic
responsiveness to b-adrenergic stimulation and increased atrial
contractility in TGF-b1 transgenic mice appear as logical
Figure 5. Contractility of isolated cardiac myocytes from wild type (WT) and TGF-b1 transgenic (TGF-b1) mice. (A) Representative
original registrations of cell shortening (dL/L) under basal conditions and upon isoprenaline stimulation (10 mM). (B) Contractile response of isolated
cardiomyocytes from WT and TGF-b1 mice to increasing concentrations of isoprenaline (n=100 in each group). (C) Contractile response of isolated
cardiomyocytes to 10 mM isoprenaline in the various treatment groups (n=97–135 in each group). *p,0.05 vs. WT.
doi:10.1371/journal.pone.0026628.g005
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cardiac myocytes with TGF-b1 (10 ng/ml) leads to upregulation of UCP2 and UCP3 mRNA (n=4 in each group). (B) Western blot analysis of UCP3
expression in mitochondria isolated from myocardial tissue of WT and TGF-b1 mice. COX-I served as a loading control, and UCP3 knockout mice
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understand why the inotropic response to b-adrenoceptor
stimulation in LV is oppositely affected. The increased atrial
contractility is likely due to a situation of diastolic LV dysfunction,
where the left atrium has to compensate for the diminished LV
filling in the hypertrophied heart (as reflected by the inversed E/A
ratio in humans). Furthermore, an impaired contractile reserve of
the LV is frequently observed in diastolic heart failure. In contrast
to ventricles, no significant influence of TGF-b1 on UCP2 and
UCP3 gene expression was observed in atrial tissue (data not
shown).
While TGF-b1 signaling has previously not been linked to
cardiac energy metabolism, our data show that stimulation of
isolated cardiac myocytes with TGF-b1 leads to an upregulation of
UCP2 and UCP3 mRNA, and that overexpression of TGF-b1 in
transgenic mice is associated with increased levels of UCP3 protein
in cardiac mitochondria. A connection between TGF-b1 and
UCPs was shown in other systems. For instance, TGF-b1 induces
UCP expression in fetal rat brown adipocytes [34]. Recently,
UCP2 was shown to be upregulated in an aortic regurgitation
model of heart failure, and UCP3 upregulation and mitochondrial
uncoupling were demonstrated in viable myocardium of chroni-
cally infarcted, failing rat hearts [35,36]. While these investigators
did not relate their findings to TGF-b1, the upregulation of
mitochondrial UCPs correlates with an increased expression of
TGF-b1 in chronic myocardial infarction and heart failure that
was shown in several animal studies as well as in human heart
(reviewed in [5,6]).
The contractile function of the heart is dependent on a sufficient
energy supply that has to be continuously adapted to the energy
demand, provided by substrate utilization, oxidative phosphory-
lation, and ATP transfer and utilization [33]. Cardiac high-energy
phosphate levels are reduced in heart failure, and they correlate
with indexes of diastolic and systolic function, and with NYHA
functional class and mortality in heart failure patients [33].
In our model, cardiac mitochondrial UCPs were upregulated
albeit contractile function at rest was normal. The functional
consequences of UCP upregulation only became evident when the
isolated myocytes or mice were challenged with b-adrenoceptor
stimulators, and the inotropic reserve was assessed. Hence, the
energy supply appeared adequate under resting conditions, but
insufficient under high work-load conditions. This correlated with
an upregulation of mitochondrial UCPs. Whether UCP upregula-
tion is adaptive or maladaptive cannot be answered from our
studies and requires further investigation. One speculate can, that
UCPs may act as part of an adaptive response in the
hypertrophied/failing heart, mainly by decreasing ROS produc-
tion and lipotoxicity [36]. However, these potential benefits are
likely to be offset by increased respiratory uncoupling. The
resulting inefficiency of oxidative phosphorylation causes a decline
in ATP transfer during high-energy phosphate metabolism. These
metabolic abnormalities may contribute to contractile dysfunction
and particularly to the loss of inotropic reserve that is characteristic
of hypertrophied myocardium in (diastolic) heart failure [33].
Mitochondrial uncoupling might therefore play an important role
in the progression from compensated hypertrophy to overt heart
failure.
In addition to TGF-b1, the findings presented herein indicate
that the b-adrenergic system is critically involved in the regulation
of UCP expression. Consistent with this idea, b-adrenoceptor
agonists were shown to increase the expression levels of UCPs in
L6 myotubes, adipose tissue, and the heart [37–39]. Likewise,
some studies have indicated that the partial prevention of
contractile LV dysfunction in animal models of heart failure by
b-blockers such as bisoprolol was associated with an improvement
of cardiac energy metabolism [40]. Here, chronic b-adrenoceptor
blockade by metoprolol restored the inotropic reserve in TGF-b1
transgenic mice, and this was accompanied by the downregulation
of the initially upregulated myocardial UCPs. The functional
relevance of UCPs in this context was demonstrated by the fact
that genipin, acting as a UCP inhibitor [32], restored the inotropic
responsiveness to b-adrenergic stimulation in isolated cardiomy-
ocytes and in vivo. This may implicate that their upregulation is
critically involved in the diminished contractile b-adrenergic
response in TGF-b1 transgenic mice. Although the data obtained
in human myocardium are based on a small number of samples
served as a negative control. The bar graph represents means 6 SEM from 7 animals in each group. (C and D) Expression of UCP2 and UCP3 mRNA in
the various treatment groups. (E) Functional role of UCPs in the heart. Inhibition of UCPs by genipin (100 mg/kgBW) restored the contractile response
to dobutamine (40 mg/kg/min) in TGF-b1 mice. (F) Genipin (5 mM) restored the contractile response to isoprenaline (10 mM) in isolated cardiac
myocytes (n=26–30 in each group).
doi:10.1371/journal.pone.0026628.g006
Figure 7. TGF-b1 (A) and UCP3 (B) expression in human heart.
Myocardial samples were obtained from non-failing myocardium (NF;
n=3), and from DCM hearts of patients who had not received b-blocker
treatment (DCM; n=5) or patients who were treated with metoprolol
(DCM-METO; n=3). *p,0.05 vs. DCM.
doi:10.1371/journal.pone.0026628.g007
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that the above mechanisms may be relevant in humans. As shown
in Figure 7, myocardial UCP3 levels were elevated in hearts from
DCM patients not receiving b-blocker treatment, while this was
not the case in patients receiving metoprolol. These data are
consistent with recent reports which indicate that energy
deficiency in heart failure is associated with increased cardiac
mitochondrial UCP expression and/or activity in humans.
Murray et al. reported that UCP2 and UCP3 were upregulated
in myocardial samples of patients with ischemia-associated
cardiomyopathy [41]. Likewise, increased UCP activity was found
in patients with obesity-related diabetic cardiomyopathy [42].
These data implicate that b-blockers may act beneficially in heart
failure at least in part by augmenting cardiac energy efficiency.
Taken together, our data demonstrate that TGF-b1 oppositely
regulates the hypertrophic and contractile response to b-
adrenergic stimulation in the heart, leading to a phenotype of
cardiac hypertrophy and myocardial dysfunction. The impairment
of the inotropic reserve in TGF-b1 hearts from transgenic mice is
linked to an upregulation of mitochondrial UCPs which influence
cardiac energy metabolism. Furthermore, our findings highlight
the critical role of the b-adrenergic system in TGF-b1-induced
cardiac phenotype and indicate that b-blockers may act benefi-
cially in cardiac hypertrophy and dysfunction at least in part by
normalizing regulatory mechanisms of cellular hypertrophy and
energy metabolism.
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